ATTACK – EU CANCER RESEARCH PROJECT – SIXTH FRAMEWORK PROGRAMME – T CELL THERAPY
December 1st, 2005
BY KEITH NUTHALLA NEW research project spending around Euro 12 million in European Union (EU) money will investigate how cancer cells evade the human immune system, maybe promoting new treatments. An international consortium of 16 partners, coordinated by Britain's University of Manchester, and including Oxford Biomedica Plc, will collaborate in the five-year ATTACK project (adoptive engineered T-cell targeting to activate cancer killing). It seeks to refine 'T-cell mediated immunotherapy', which engineers T-cells with artificial receptors targeting tumours. ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.